- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 4.20 Å
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 9 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN- BMA- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)-beta-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-BMA-MAN.2: 14 residues within 4Å:- Chain A: H.290, N.292, T.372
- Chain C: Y.32, R.98, W.101, S.103, Y.106, Y.111, N.113, D.115
- Chain D: Y.51, K.55, S.58
1 PLIP interactions:1 interactions with chain C- Hydrogen bonds: C:Y.32
NAG-NAG-BMA-MAN-MAN-BMA-MAN.9: 14 residues within 4Å:- Chain E: H.290, N.292, T.372
- Chain G: Y.32, R.98, W.101, S.103, Y.106, Y.111, N.113, D.115
- Chain H: Y.51, K.55, S.58
1 PLIP interactions:1 interactions with chain G- Hydrogen bonds: G:Y.32
NAG-NAG-BMA-MAN-MAN-BMA-MAN.16: 14 residues within 4Å:- Chain I: H.290, N.292, T.372
- Chain K: Y.32, R.98, W.101, S.103, Y.106, Y.111, N.113, D.115
- Chain L: Y.51, K.55, S.58
1 PLIP interactions:1 interactions with chain K- Hydrogen bonds: K:Y.32
- 3 x NAG- NAG- BMA- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-NAG.3: 8 residues within 4Å:- Chain A: N.261, N.262, N.263
- Chain D: Q.1, Y.32, Y.93, G.95, S.96
1 PLIP interactions:1 interactions with chain D- Hydrogen bonds: D:Q.1
NAG-NAG-BMA-NAG.10: 8 residues within 4Å:- Chain E: N.261, N.262, N.263
- Chain H: Q.1, Y.32, Y.93, G.95, S.96
1 PLIP interactions:1 interactions with chain H- Hydrogen bonds: H:Q.1
NAG-NAG-BMA-NAG.17: 8 residues within 4Å:- Chain I: N.261, N.262, N.263
- Chain L: Q.1, Y.32, Y.93, G.95, S.96
1 PLIP interactions:1 interactions with chain L- Hydrogen bonds: L:Q.1
- 6 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.4: 2 residues within 4Å:- Chain A: N.399
- Chain D: Y.32
1 PLIP interactions:1 interactions with chain D- Hydrophobic interactions: D:Y.32
NAG-NAG-BMA.6: 4 residues within 4Å:- Chain A: N.299, Q.303, N.351, T.361
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.11: 2 residues within 4Å:- Chain E: N.399
- Chain H: Y.32
1 PLIP interactions:1 interactions with chain H- Hydrophobic interactions: H:Y.32
NAG-NAG-BMA.13: 4 residues within 4Å:- Chain E: N.299, Q.303, N.351, T.361
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.18: 2 residues within 4Å:- Chain I: N.399
- Chain L: Y.32
1 PLIP interactions:1 interactions with chain L- Hydrophobic interactions: L:Y.32
NAG-NAG-BMA.20: 4 residues within 4Å:- Chain I: N.299, Q.303, N.351, T.361
No protein-ligand interaction detected (PLIP)- 27 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.22: 3 residues within 4Å:- Chain A: N.223, R.403
- Ligands: NAG.30
Ligand excluded by PLIPNAG.23: 3 residues within 4Å:- Chain A: Q.322, N.345, S.347
Ligand excluded by PLIPNAG.24: 1 residues within 4Å:- Chain A: N.351
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain A: N.119, E.128
Ligand excluded by PLIPNAG.26: 2 residues within 4Å:- Chain A: K.319, N.321
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain A: N.237
- Ligands: NAG-NAG.7
Ligand excluded by PLIPNAG.28: 2 residues within 4Å:- Chain A: G.56, N.57
Ligand excluded by PLIPNAG.29: 2 residues within 4Å:- Chain A: N.190, N.202
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain A: P.252, N.405
- Ligands: NAG.22
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain E: N.223, R.403
- Ligands: NAG.39
Ligand excluded by PLIPNAG.32: 3 residues within 4Å:- Chain E: Q.322, N.345, S.347
Ligand excluded by PLIPNAG.33: 1 residues within 4Å:- Chain E: N.351
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain E: N.119, E.128
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain E: K.319, N.321
Ligand excluded by PLIPNAG.36: 2 residues within 4Å:- Chain E: N.237
- Ligands: NAG-NAG.14
Ligand excluded by PLIPNAG.37: 2 residues within 4Å:- Chain E: G.56, N.57
Ligand excluded by PLIPNAG.38: 2 residues within 4Å:- Chain E: N.190, N.202
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain E: P.252, N.405
- Ligands: NAG.31
Ligand excluded by PLIPNAG.40: 3 residues within 4Å:- Chain I: N.223, R.403
- Ligands: NAG.48
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain I: Q.322, N.345, S.347
Ligand excluded by PLIPNAG.42: 1 residues within 4Å:- Chain I: N.351
Ligand excluded by PLIPNAG.43: 2 residues within 4Å:- Chain I: N.119, E.128
Ligand excluded by PLIPNAG.44: 2 residues within 4Å:- Chain I: K.319, N.321
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain I: N.237
- Ligands: NAG-NAG.21
Ligand excluded by PLIPNAG.46: 2 residues within 4Å:- Chain I: G.56, N.57
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain I: N.190, N.202
Ligand excluded by PLIPNAG.48: 3 residues within 4Å:- Chain I: P.252, N.405
- Ligands: NAG.40
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Saunders, K.O. et al., Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science (2019)
- Release Date
- 2019-12-18
- Peptides
- CH848 10.17 DT gp120: AEI
Envelope glycoprotein gp160: BFJ
DH270 UCA3 Fab Heavy Chain: CGK
DH270 UCA3 Fab Light Chain: DHL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
EI
IB
BF
FJ
JC
CG
GK
KD
DH
HL
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 4.20 Å
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 9 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN- BMA- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)-beta-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 6 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 27 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Saunders, K.O. et al., Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science (2019)
- Release Date
- 2019-12-18
- Peptides
- CH848 10.17 DT gp120: AEI
Envelope glycoprotein gp160: BFJ
DH270 UCA3 Fab Heavy Chain: CGK
DH270 UCA3 Fab Light Chain: DHL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
EI
IB
BF
FJ
JC
CG
GK
KD
DH
HL
L